AXSM is trading 4.1% up now at $252.41 following the initiation of its FOCUS-2 Phase 3 trial for solriamfetol in children with ADHD. - This significant pipeline development drives stock-specific enthusiasm amidst broader biotech sector momentum. - Wall Street maintains bullish price targets and Strong Buy-style ratings on Axsome.